Abstract
Gastric cancer is the second leading cause of cancer mortality and the fourth most common malignancy worldwide. An estimated 21,600 new cases of gastric cancer were diagnosed in the United States in 2013, and more than 10,000 people died of the disease. Although treatment of resectable gastric cancer has improved over the last two decades, little progress has been made in advanced gastric cancer. After a patient has progressed on first-line treatment, no second-line treatment for gastric cancer has yet been approved by the US Food and Drug Administration. Several clinical trials for therapies targeting aberrant signaling pathways either have concluded or are underway. These targeted treatments have the potential to substantially improve patient outcomes. However, with each new treatment, clinicians must stay abreast of a new wave of data on underlying mechanisms, efficacy, and safety, to provide their patients with optimal care. The magnitude of information surrounding emerging treatments for advanced gastric cancer can be daunting; this monograph will provide hospital-based clinicians with a much-needed, concise overview of the available data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
